Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Incannex HealthcareIXHL +3.80%32 3-1 Month Momentum % is -18.30% as of Aug. 16, 2026. GuruFocus rates IXHL with a GF Score™ of 32/100. The stock has 2 warning signs investors should review. Among 1,026 Drug Manufacturers companies, Incannex Healthcare ranks worse than 78.07% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-08-16), Incannex Healthcare's 3-1 Month Momentum % is -18.30%.
The industry rank for Incannex Healthcare's 3-1 Month Momentum % or its related term are showing as below:
IXHL's 3-1 Month Momentum % is ranked worse than 78.07% of 1026
companies
in the Drug Manufacturers industry
Industry Median: -5.74
vs IXHL: -18.30
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Incannex Healthcare 3-1 Month Momentum % Related Terms
IXHL vs ETST, SCYX, INIS: 3-1 Month Momentum % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Incannex Healthcare's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Incannex Healthcare 3-1 Month Momentum % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Incannex Healthcare's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Incannex Healthcare's 3-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Incannex Healthcare (IXHL) has a 3-1 Month Momentum % of -18.30% as of Aug. 16, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Incannex Healthcare and its competitors. According to the industry distribution chart, Incannex Healthcare ranks #801 out of 1026 companies in the Drug Manufacturers industry, placing it in the top 78.1%.
Is Incannex Healthcare's 3-1 Month Momentum % too high?
Incannex Healthcare's current 3-1 Month Momentum % is -18.30%. Based on the distribution chart, Incannex Healthcare ranks #801 out of 1026 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Incannex Healthcare has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Incannex Healthcare's 3-1 Month Momentum % compare to ETST and SCYX?
According to the Drug Manufacturers industry distribution chart, Incannex Healthcare ranks #801 out of 1026 companies for 3-1 Month Momentum %. This places Incannex Healthcare in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Drug Manufacturers company?
A good 3-1 Month Momentum % depends on the Drug Manufacturers industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Incannex Healthcare and its competitors. Incannex Healthcare's current 3-1 Month Momentum % is -18.30%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Incannex Healthcare stock overvalued right now?
Incannex Healthcare (IXHL) has a current 3-1 Month Momentum % of -18.30%. The current 3-1 Month Momentum % is -18.30%. Incannex Healthcare's overall GF Score™ is 32/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Incannex Healthcare (IXHL), the current 3-1 Month Momentum % is -18.30% as of Aug. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Incannex Healthcare Inc is a clinical stage pharmaceutical company developing medical cannabis products for the treatment of Obstructive Sleep Apnea (OSA), Traumatic Brain Injury (TBI)/Concussion, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Inflammatory Lung Conditions. The company has an Australian license to import, export, and distribute medicinal cannabis products and has launched a line of cannabinoid products. The Company operates and manages its business as one reportable and operating segment, which is the Research and Development of the use of psychedelic medicine and therapies.
32GF Score
Get the complete analysis for IXHL
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IXHL has been successfully added to your 
